The biotech sector is filled with mispriced securities after an era of easy money in 2020, according to Janus Henderson’s Agustin Mohedas.
![](https://s34456.pcdn.co/wp-content/uploads/2023/11/Mohedas_Agustin_3B5A9682_1900x1800-3-640x360.png)
The biotech sector is filled with mispriced securities after an era of easy money in 2020, according to Janus Henderson’s Agustin Mohedas.
Part of the Mark Allen Group.